Cerniltonr efficiency and safety in treatment of patients with chronic abacterial prostatitis and BPH evaluation recent

CerniltonR is a medication which active components are microbiologically fermented pollen extract of various plants. Medicine has antiedemic and anti-inflammatory activity, capable to inhibit 5-α reductase thus slowing down prostate cells proliferation. Also improves voiding by α-1 receptors blocking and direct relaxation activity on urethral smooth muscles. CerniltonR evaluation of efficiency and safety in patients with prostate deceases recent researches reviewed. 60 publications dedicated to this topic were found through MedLine. The earliest one is dated after 1962. Fundamental investigations of CerniltonR mechanism of action were done. Numerous controlled randomized clinical studies with quantity of patients are still going on. Different dosage long term results already published. Due to long-term studies demonstrate continuous efficiency and safety of CerniltonR. This allows to recommend CerniltonR as a supporting and prophylactic medicine. Thereby CerniltonR is highly-effective, safe medication of choice in treatment of patientswith chronic abacterial prostatitis and BPH.